Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Income from Continuing Operations: 2022-2024

Historic Income from Continuing Operations for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to -$60.9 million.

  • Orchestra BioMed Holdings' Income from Continuing Operations fell 35.02% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.1 million, marking a year-over-year decrease of 33.72%. This contributed to the annual value of -$60.9 million for FY2024, which is 27.88% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Income from Continuing Operations stood at -$60.9 million for FY2024, which was down 27.88% from -$47.7 million recorded in FY2023.
  • Over the past 5 years, Orchestra BioMed Holdings' Income from Continuing Operations peaked at -$32.7 million during FY2022, and registered a low of -$60.9 million during FY2024.
  • Its 3-year average for Income from Continuing Operations is -$47.1 million, with a median of -$47.7 million in 2023.
  • Data for Orchestra BioMed Holdings' Income from Continuing Operations shows a maximum YoY plummeted of 45.93% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Orchestra BioMed Holdings' Income from Continuing Operations stood at -$32.7 million in 2022, then tumbled by 45.93% to -$47.7 million in 2023, then fell by 27.88% to -$60.9 million in 2024.